Research funder · United States

Children's Tumor Foundation

Foundation dedicated to improving the health and well-being of individuals and families affected by neurofibromatosis

ctf.org

Grants since 2016: 436
Awarded, last 5 years (where amounts are published): 28.1M
Funded works, last 5 years: 115
Funded works, all time: 426

Grants

2018–2020 · award

The Role of Cap-dependent translation in NF1-assiciated MPNSTs

Dong Hyuk Ki

108kNeurofibromatosis and Schwannoma Cases

2018–2023 · award

Developing Evidence-Based Criteria for Initiating Treatment for Neurofibromatosis Type 1 Associated Optic Pathway Glioma

Sabine Mueller

Neurofibromatosis and Schwannoma Cases

2018–2021 · award

Validation and development of NF volumetric analysis software (renewal)

Gordon Harris

99kNeurofibromatosis and Schwannoma Cases

2017–2019 · award

Molecular and signaling mechanisms of malignant transformation in peripheral nerve sheath tumors

Lai Man Natalie Wu

108kNeurofibromatosis and Schwannoma Cases

2017–2022 · award

Developing Evidence-Based Criteria for Initiating Treatment for Neurofibromatosis Type 1 Associated Optic Pathway Glioma

Simone Ardern-Holmes

6 260Neurofibromatosis and Schwannoma Cases

2017–2022 · award

Developing Evidence-Based Criteria for Initiating Treatment for Neurofibromatosis Type 1 Associated Optic Pathway Glioma

John Crawford

2 240Neurofibromatosis and Schwannoma Cases

2017–2019 · award

Visual Field Outcomes in Pediatric Patients with NF-1-associated Optic Pathway Gliomas

Gena Heidary · Boston Children's Hospital

150kNeurofibromatosis and Schwannoma Cases

2017–2022 · award

Developing Evidence-Based Criteria for Initiating Treatment for Neurofibromatosis Type 1 Associated Optic Pathway Glioma

Nicole Ullrich

3 080Neurofibromatosis and Schwannoma Cases

2017–2019 · award

NFCN - Vanderbilt University Medical Center/Vanderbilt-Ingram Cancer Center

Paul Moots

8 600

2017–2020 · award

Synodos Schwannomatosis

Antonio Iavarone

157.7kNeurofibromatosis and Schwannoma Cases

2017–2022 · award

Developing Evidence-Based Criteria for Initiating Treatment for Neurofibromatosis Type 1 Associated Optic Pathway Glioma

Kevin Bielamowicz

4 400Neurofibromatosis and Schwannoma Cases

2017–2019 · award

Exploiting Synthetic Lethality to Reveal Novel Vulnerabilities in NF1 Tumorigenesis

Kyle Williams

108kNeurofibromatosis and Schwannoma Cases

2017–2022 · award

Developing Evidence-Based Criteria for Initiating Treatment for Neurofibromatosis Type 1 Associated Optic Pathway Glioma

Miriam Bornhorst

2 200Neurofibromatosis and Schwannoma Cases

2017–2020 · award

Synodos Schwannomatosis

Laura Papi

130kNeurofibromatosis and Schwannoma Cases

2017–2020 · award

Synodos Schwannomatosis

Kimberly Ostrow

10kNeurofibromatosis and Schwannoma Cases

2017–2022 · award

Developing Evidence-Based Criteria for Initiating Treatment for Neurofibromatosis Type 1 Associated Optic Pathway Glioma

Sarah Leary

Neurofibromatosis and Schwannoma Cases

2017–2022 · award

Developing Evidence-Based Criteria for Initiating Treatment for Neurofibromatosis Type 1 Associated Optic Pathway Glioma

Adam Esbenshade

440Neurofibromatosis and Schwannoma Cases

2017–2022 · award

Developing Evidence-Based Criteria for Initiating Treatment for Neurofibromatosis Type 1 Associated Optic Pathway Glioma

Cynthia Campen

990Neurofibromatosis and Schwannoma Cases

2017–2020 · award

Synodos Schwannomatosis

Sheila Mansouri

651.2kNeurofibromatosis and Schwannoma Cases

2017–2022 · award

Reliability and Validity of Computerized Cognitive Outcome Tools in NF1

Karin Walsh · Children's National

150k

2017–2019 · award

NFCN - Riley Hospital for Children IU Health Physicians

Lisa Smith

3 000

2017–2019 · award

NFCN - Mayo Clinic Arizona

Radhika Dhamija

10k

2017–2021 · award

A Phase-II Trial on the Effect of Low-Dose versus High-Dose Vitamin D Supplementation on Bone Mass in Adults with NF1 (Neurofibromatosis Type 1)

David Viskochil · University of Utah

146.3kNeurofibromatosis and Schwannoma Cases

2017–2020 · award

Synodos Schwannomatosis

Anat Stemmer-Rachamimov

30kNeurofibromatosis and Schwannoma Cases

2017–2019 · award

NFCN - UCLA Medical Center

Phioanh Leia Nghiemphu

12k

2017–2019 · award

NFCN - Stanford/Lucile Packard Children's Hospital

Cynthia Campen

7 000

2017–2019 · award

NFCN - University of Wisconsin/American Family Children's Hospital

Neha Patel

8 000

2017–2019 · award

NFCN - Moffitt Cancer Center

Xia Wang

11.7k

2016–2019 · award

NFCN - Seattle Children's Hospital

Aimee Sato

9 000

2016–2018 · award

Evaluation of Mebendazole as Chemoprevention in a Neurofibromatosis 1 Transgenic Mouse Model

Verena Staedtke

85kNeurofibromatosis and Schwannoma Cases

2016–2021 · award

Developing Evidence-Based Criteria for Initiating Treatment for Neurofibromatosis Type 1 Associated Optic Pathway Glioma

Jeffrey Allen

440Neurofibromatosis and Schwannoma Cases

2016–2019 · award

NFCN - Rainbow Babies and Children's Hospital

Deborah Rukin Gold

10k

2016–2019 · award

NFCN - St. Joseph's Regional Medical Center

Punita Gupta

15.5k

2016–2019 · award

NFCN - Children's Hospital Colorado

Jennifer Janusz

15.7k

2016–2019 · award

NFCN - Boston Children's Hospital

David Miller

11k

2016–2019 · award

NFCN - Washington University/St. Louis Children's Hospital

David Gutmann

5 000

2016–2019 · award

NFCN- University of North Carolina Hospitals

Robert Greenwood

2016–2019 · award

NFCN - Children's Hospital Los Angeles

Tena Rosser

12.3k

2016–2018 · award

NFTC 2017- Testing of terapeutics in the JMML model

Kevin Shannon

191.4kProtein Degradation and Inhibitors

2016–2019 · award

NFCN - University of Utah

David Viskochil

18k